NCT07083947进行中（未招募）不适用
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Effect of Herbal Compositions CL19183 and CL24212 on Body Weight, Body Composition and Metabolic Health in Overweight Subjects
ApexCPG LLC2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2025年7月16日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
- 试验地点
- 2
- 主要终点
- Change from baseline to the end of the study period in Body weight
研究概览
简要总结
The Purpose of the study is to evaluate the efficacy of herbal composition CL19183 and CL24212 on body weight, body composition and metabolic health in overweight subjects.
详细描述
A total of 150 male and female subjects aged between 25 and 55 years will be included in the study. Assessment of inclusion and exclusion criteria will be done based on clinical and laboratory investigations. The eligible subjects will be randomized as per the computer-generated randomization list. The subjects will be assigned to either CL19183:450 mg or CL24212:300 mg or Placebo arm at 1:1:1 ratio. The subjects will be instructed to take one capsule daily in the morning after breakfast for 16 weeks. Apart from primary and secondary outcomes, the study will also record the vital signs and adverse events to evaluate the herbal composition safety and tolerability. The safety assessment of the CL19183 and CL24212 will also include routine laboratory investigations on blood, urine and clinical chemistry at screening and the final visit of the intervention
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 22 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •1. Healthy male and female subjects aged between 25-55 years with body mass index (BMI) of 25-29.9 kg/m
- •2. Subjects with sedentary lifestyle, no regular athletic or sports activities.
- •Subjects willing to participate in walking-exercise (5 days a week, 30 min per day) over study duration.
- •4. Subjects with normal thyroid hormone profile.
- •Subjects agreed to consume recommended standard diet.
- •Subjects who are willing to abstain from alcohol, coffee, tea, cola, energy drinks & chocolate for at least 24 hrs. prior to visits and final visit.
- •7. Subjects who are non-smokers.
- •Subject agrees to maintain diet tracker.
- •Subject considered generally healthy as per health history and routine clinical investigations during screening.
- •10. Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®, or double-barrier and have a negative pregnancy test at the screening visit.
- •11. Ability to understand the risks/benefits of the protocol and willing to sign the written informed consent.
排除标准
- •1. Subjects who were taking medications which affect the metabolic rate (e.g. antidepressants, beta-blockers, hormones, etc.).
- •2. Subjects on weight loss practices, usage of weight reduction supplements/nutrition products will be excluded.
- •3. Subjects underwent treatment for COVID 19 within last 3 months or tested positive during the study will be excluded.
- •4. Subjects participated in any weight loss programs within 3 months.
- •Subjects who are diabetic and/or hypertensive.
- •Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, malignancies.
- •7. Subjects taking medications for or suffering from a medical condition that could impact results related to metabolism (e.g., thyroid disorders, diabetes, mental disorders such as anxiety or depression, heart disease, arthritis, cancer).
- •8. Subjects with HIV Positive.
- •Female subjects, who are pregnant, breast feeding or planning to become pregnant during the study.
- •10. Subjects having history of psychiatric disorder that may impair the ability of subjects to provide written informed consent.
- •11. Any other condition that, in the opinion of the investigator, would adversely affect the subject's ability to complete the study or its measures.
- •12. Use of nutritional supplements (e.g., creatine, protein drinks, amino acids, or vitamins) or ergogenic aids and caffeinated and not caffeinated thermogenics within 30 days prior to the study.
- •13. Subjects who are participated or currently participating in another clinical trial within 30 days prior to screening.
结局指标
主要结局
Change from baseline to the end of the study period in Body weight
时间窗: Week 0 (Baseline), Week 2, Week 4, Week 8, Week 12 & Week 16
The subject's body weight is measured using a digital weighing scale. An improvement is indicated when the body weight falls within the normal range based on the subject's demographic characteristics.
次要结局
- Change from baseline to the end of the study period in Lipid profile (including amyloid A)(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in Lipid profile (including Apo B)(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in total glucagon-like peptide 1(GLP- 1)(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in C-Peptide(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in Glucagon(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in VCAM-1(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in ICAM- 1(ICAM-1 is typically expressed at low levels on various cell types, including endothelial cells (lining blood vessels), immune cells (like leukocytes), and epithelial cells. ICAM-1 expression is significantly upregulated in adipose tissue in obesity.)
- Change from baseline to the end of the study period in Body mass index (BMI)(Screening, Week 0 (Baseline),Week 2, Week 4, Week 8, Week 12 & Week 16)
- Change from baseline to the end of the study period in Body composition using DEXA (including fat and lean mass)(Week 0 (Baseline), Week 8& Week 16)
- Change from baseline to the end of the study period in Waist (WC)(Week 0 (Baseline),Week 2, Week 4,Week 8,Week 12,Week 16)
- Change from baseline to the end of the study period in Hip circumference (HC)(Week 0 (Baseline),Week 2, Week 4,Week 8,Week 12,Week 16)
- Change from baseline to the end of the study period in Waist to hip ratio (WHR)(Week 0(Baseline), Week 2, Week 4, Week 8, Week 12& Week 16)
- Change from baseline to the end of the study period in Lipid profile (including amyloid A)(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in Lipid profile (including Apo B)(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in Adiponectin(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in Ghrelin(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in total glucagon-like peptide 1(GLP- 1)(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in C-Peptide(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in Glucagon(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in VCAM-1(Week 0 (Baseline), Week 8 & Week 16)
- Change from baseline to the end of the study period in ICAM- 1(ICAM-1 is typically expressed at low levels on various cell types, including endothelial cells (lining blood vessels), immune cells (like leukocytes), and epithelial cells. ICAM-1 expression is significantly upregulated in adipose tissue in obesity.)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Effect of herbal compositions on body weight, body composition and metabolic health in overweight subjectsCTRI/2025/06/088669Apex CPG LLC150
已完成
不适用
A clinical study to assess effect of an herbal product in improving testosterone levels in healthy young malesCTRI/2018/11/016337Laila Nutraceuticals120
已完成
2 期
A Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in WomenMenopausal SymptomsNCT02269891KGK Science Inc.119
已完成
3 期
Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic RhinosinusitisChronic SinusitisNCT01706484Bionorica SE927
已完成
不适用
Clinical study to measure the effect of natural product in muscle pain and related swelling and stress in healthy subjects.CTRI/2022/06/043370AureaBiolabs Private Limited110